Authors: Hanan Ahmed Wahba Hend Ahmed ElHadaad Ehab Atef AbdEllatif
Publish Date: 2011/06/26
Volume: 29, Issue: 3, Pages: 1693-1698
Abstract
Evaluation of the feasibility and efficacy of neoadjuvant concurrent chemoradiotherapy CRT with capecitabine and oxaliplatin in patients with locally advanced esophageal cancer Fortytwo patients were eligible for the study The chemotherapy during CRT consisted of two cycles of intravenous oxaliplatin of 120 mg/m2 on day 1 and oral capecitabine 825 mg/m2 twice daily on days 1–14 at 3week intervals The radiotherapy 18 Gy/fraction/day to a total dose of 45 Gy was delivered to the primary tumor site and regional lymph node All patients completed the planned treatment Overall clinical response rate was 548 with complete response in 167 while pathological response rate was 38 Anemia was the commonest hematologic toxicity 523 with grade 3 in 47 and esophagitis was the commonest nonhematologic toxicity 595 with grade 3 and 4 in 95 No treatmentrelated death was observed After a median followup duration of 19 months the 2year survival rate was 42 median survival time was 20 months 95CI 1380226198 while 2year progressionfree survival PFS rate was 325 with median PFS time of 15 months 95CI 1004219958 Neoadjuvant concurrent CRT with capecitabine and oxaliplatin was found to be well tolerated and effective in patients with locally advanced esophegeal cancer however these results should be further evaluated in a phase III study
Keywords: